Full speed ahead for Cereno Scientific11 September, 2019
Lately, Cereno Scientific has had a great deal to communicate. So far, the year has meant an oversubscribed rights issue, a patent approval and an application to commence phase II studies with the company’s main candidate CS1. When BioStock met CEO Sten R. Sörensen at LSX Nordic Congress it was obvious that the company does not intended to rest on its laurels for the remainder of the year. As soon as LSX was over Cereno Scientific headed to the European Society of Cardiology 2019 conference in Paris, and the company will be attending a number of similar events during autumn.
To read the full article on BioStock, click here.